Results 341 to 350 of about 14,299,063 (394)

A genetic association study of circulating coagulation factor VIII and von Willebrand factor levels.

Blood
de Vries PS, Reventun P, Brown MR, Heath AS, Huffman JE, Le NQ, Bebo A, Brody JA, Temprano-Sagrera G, Raffield LM, Ozel AB, Thibord F, Jain D, Lewis JP, Rodriguez BAT, Pankratz N, Taylor KD, Taylor KD, Polasek O, Chen MH, Yanek LR, Carrasquilla GD, Marioni RE, Kleber ME, Trégouët DA, Yao J, Li-Gao R, Joshi PK, Trompet S, Martinez-Perez A, Ghanbari M, Howard TE, Reiner AP, Arvanitis M, Ryan KA, Bartz TM, Rudan I, Faraday N, Linneberg A, Ekunwe L, Davies G, Delgado GE, Suchon P, Guo X, Rosendaal FR, Klaric L, Noordam R, van Rooij F, Curran JE, Wheeler MM, Osburn WO, O'Connell JR, Boerwinkle E, Beswick A, Psaty BM, Kolcic I, Souto JC, Becker LC, Hansen T, Doyle MF, Harris SE, Moissl AP, Deleuze JF, Rich SS, van Hylckama Vlieg A, Campbell H, Stott DJ, Soria JM, de Maat MPM, Almasy L, Brody LC, Auer PL, Mitchell BD, Ben-Shlomo Y, Fornage M, Hayward C, Mathias RA, Kilpeläinen TO, Lange LA, Cox SR, März W, Morange PE, Rotter JI, Mook-Kanamori DO, Wilson JF, van der Harst P, Jukema JW, Ikram MA, Blangero J, Kooperberg C, Desch KC, Johnson AD, Sabater-Lleal M, Lowenstein CJ, Smith NL, Morrison AC.   +95 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Factor VIII replacement is still the standard of care in haemophilia A.

Blood transfusion = Trasfusione del sangue, 2019
Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status.
L. Aledort, P. Mannucci, W. Schramm, M. Tarantino   +3 more
semanticscholar   +1 more source

Studies on the Characterization of Factor VIII and a Co-factor VIII

Thrombosis and Haemostasis, 1974
SummaryFactor VIII occurs in the body in two different forms. In lymph factor VIII is bound to chylomicra. In plasma, factor VIII is bound to a protein.After delipidation of chylomicra we obtained a glycoprotein with a high polysaccharide content and a molecular weight of approx.
H. L. M. A Vandenbussche-Scheffers, M. M. P Paulssen, P. B Spaan, T de Jong, M. C Planje   +4 more
openaire   +3 more sources

Factor Viii Inhibitors [PDF]

, 2001
The differential diagnosis in the bleeding patient includes inhibitory antibodies to blood coagulation proteins. Factor VIII (fVIII) is the most commonly targeted coagulation protein by the immune system. FVIII inhibitors arise as alloantibodies in transfused hemophiliacs and as autoantibodies in nonhemophiliac populations (1, 2, 3, 4). They develop in
John F. Healey, Rachel T. Barrow, Ernest T. Parker, Pete Lollar   +3 more
openaire   +2 more sources

Factor VIII immunogenicity

Haemophilia, 1998
Summary. The immunogenicity of factor VIII depends on the interaction of multiple parametres including host susceptibility and characteristics of the factor VIII preparations. We briefly review here the basic mechanisms by which tolerance to self is established, maintained, and possibly broken in the context of haemophilia A, with special emphasis on ...
C. A. Lee, C. M. Kessler, D. Varon, U. Martinowitz, M. Heim, M. G. JACQUEMIN, J.‐M. R. SAINT‐REMY   +6 more
openaire   +3 more sources

Factor VIII activity and factor VIII related antigen in newborns [PDF]

European Journal of Pediatrics, 1978
Factor VIII procoagulant activity and factor VIII related antigen were examined in 20 full-term and preterm newborn infants during the first days of life. The control group involved 15 adults volunteers. Factor VIII activity was estimated by a one-stage test and factor VIII related antigen was determined by immunelectrophoresis according to Laurell ...
B. Scheidt, B. Maak, J. Frenzel
openaire   +2 more sources

Heparin and Factor VIII

Scandinavian Journal of Haematology, 1984
New approaches and techniques for improving source material collection and factor VIII production at Blood Bank level have been reported recently. Heparin has shown to be of great importance in increasing both yield and stability of factor VIII in the purification and concentration process.
P. C. Das, C. Th. Smit Sibinga
openaire   +3 more sources

Autoantibodies to factor VIII

Autoimmunity Reviews, 2002
Anti-Factor VIII (FVIII) antibodies represent a unique model to study the relationship between natural autoreactivity (natural antibodies to FVIII of healthy individuals) and disease-associated autoimmunity ('spontaneous' FVIII inhibitors of patients with anti-FVIII autoimmune disease) to a single human protein antigen.
Michel D. Kazatchkine, Jagadeesh Bayry, Dipika Mohanty, Sébastien Lacroix-Desmazes, Namita Misra, Srini V. Kaveri   +5 more
openaire   +3 more sources

Factor VIII inhibitors

Haemophilia, 1995
The development of a Factor VIII inhibitor, an antibody that blocks its procoagulant function, is one of the most serious complications of hemophilia A treatment. Similar antibodies are also recognized as a rare cause of bleeding in previously healthy individuals who develop autoimmune anti-Factor VIII antibodies.
openaire   +6 more sources

Antihemophilic Factor (Factor VIII)

Annals of Internal Medicine, 1978
Antihemophilic factor (Factor VIII) is an agent in normal plasma that corrects the coagulative defect of classic hemophillia. The plasma of hemophiliacs contains normal amounts of a variant of antihemophilic factor deficient in clot-promoting properties. In contrast, von Willebrand's disease is usually associated with a true deficiency of this protein.
openaire   +3 more sources